Digoxin (NSC 95100)

Catalog No.S4290

For research use only.

Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.

Digoxin (NSC 95100) Chemical Structure

CAS No. 20830-75-5

Selleck's Digoxin (NSC 95100) has been cited by 6 Publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Other ATPase Products

Biological Activity

Description Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.
Targets
Na,K-ATPase α2β3 [1] Na,K-ATPase α2β1 [1] Na,K-ATPase α1β1 [1]
42.8 nM(Ki) 58.7 nM(Ki) 268 nM(Ki)
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
rat hepatocytes NWqw[IdxTnWwY4Tpc44h[XO|YYm= MkjwSJJ2\yC3cIThb4UhcW5icnH0JIhmeGG2b3P5eIV{NCCNbU2wMlE5KM7:TR?= Mk\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Mk[2NVkoRjJyOUK2OlE6RC:jPh?=
human hepatocytes M4DaemZ2dmO2aX;uJIF{e2G7 NWC2WoRTOC5yNTD0c{AyOCC3TR?= NYLXb3ZQTHK3ZzD1dJRic2ViaX6gd4Fv\HerY3itZ5VtfHW{ZXSgbJVu[W5iaHXwZZRw[3m2ZYOgZZQhOC5yNTD0c{AyOCC3TTDheEA{PyCmZXfDJIJ6KE2rY3jh[Yxqey2PZX70[Y4hc2mwZYTpZ5Mwe2OrboTpcIxifGmxbjDzdIVkfHKxc3PvdJktKEuvPUKuN|kh|ryP Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Mk[2NVkoRjJyOUK2OlE6RC:jPh?=
LLC-PK1 MYHGeY5kfGmxbjDhd5NigQ>? MV;UVH9VWkGQU2DPVnRGWjpiaX7obYJqfGmxbjDv[kBGOjF5YnX0ZWchfXC2YXvlJIlvKE:jdICyMYV5eHKnc4PpcochVEyFLWDLNUBk\WyuczygT4k:OC5yM{hOwG0> M3y2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNEC4OVU4Lz5zMUSwPFU2PzxxYU6=
High Five (BTI-TN5B1-4) M2\EO2Z2dmO2aX;uJIF{e2G7 NFnwWplVWF:WUlHOV3BQWlSHUkqgRXRRKGi7ZILvcJl{cXNiaX6gcYVu[nKjbnWg[pJi[3Srb36g[pJwdSCKaXfoJGZqfmViKFLUTU1VVjWEMT20LUBk\WyuczygT40:OjVwOd88US=> M1XmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{i1Olg1Lz5zMUe4OVY5PDxxYU6=
LLC-PK1 NETINVRHfW6ldHnvckBie3OjeR?= MVPUVH9VWkGQU2DPVnRGWjpiaX7obYJqfGmxbjDv[kBV[XW{b3Poc4xifGVidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU2l;MD61PO69VQ>? NV\DPIk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3PVI3QTRpPkGxO|kzPjl2PD;hQi=>
LLC-PK1 MVXGeY5kfGmxbjDhd5NigQ>? MkDJWHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDPZZRxOi2neIDy[ZN{cW6pIFzMR{1RUzFiY3XscJMtKEuvPUGuNFfPxE1? MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OUK2PVQoRjFzN{myOlk1RC:jPh?=
LLC-PK1 MnP6SpVv[3Srb36gZZN{[Xl? M17MNXRRZ1SUQV7TVG9TXEWUOjD1dJRic2ViaX6gU4F1eDJvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNbU2wMlI4Qc7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTh6M{[0NUc,OTF6OEO2OFE9N2F-
MDCK NVL6[YhWTnWwY4Tpc44h[XO|YYm= M{Ow[nRRZ1SUQV7TVG9TXEWUOjDj[YxtKGGlY4XteYxifGmxbjDpckBQSVSSNFOxMYV5eHKnc4PpcochVUSFSzDj[YxteyxiS329O{45|ryP MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR7OUO2NFQoRjF2OUmzOlA1RC:jPh?=
MDCK NFjDVodHfW6ldHnvckBie3OjeR?= NVrselM4XFChVGLBUnNRV1KWRWK6JINmdGxiYXPjeY12dGG2aX;uJIlvKE:DVGC0R|Eu\XiycnXzd4lv\yCPRFPLJINmdGy|LDDLcV05|ryP MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDl7M{[wOEc,OTR7OUO2NFQ9N2F-
TK10 MVrDfZRwfG:6aXPpeJkh[XO|YYm= NXLFR4tEPDhiaILz MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUT|ExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6wNVQ3|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjNyOUOxOUc,OTZ|MEmzNVU9N2F-
MCF7 MoPTR5l1d3SxeHnjbZR6KGG|c3H5 M1fFSVQ5KGi{cx?= MlfyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFI1Oc7:TR?= MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ|MEmzNVUoRjF4M{C5N|E2RC:jPh?=
K562 NFPFOoJEgXSxdH;4bYNqfHliYYPzZZk> MoHWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{BjgSC[VGSgZZN{[XluIFnDOVA:OC5yMkiy{txO NIjRNno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
UACC62 MV7DfZRwfG:6aXPpeJkh[XO|YYm= M{iyflQ5KGi{cx?= M2nlVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVCS0N4MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODJ7Nd88US=> NUi3SGJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFk{OTVpPkG2N|A6OzF3PD;hQi=>
HeLa MYTDfZRwfG:6aXPpeJkh[XO|YYm= MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHKncHzpZ4F1cW:wIHL5JIlu[WerbnegZY5idHm|aYO= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB4NkC1OUc,OThyNk[wOVU9N2F-
HeLa NHLUO4lHfW6ldHnvckBie3OjeR?= NGWzboRKdmirYnn0bY9vKG:oIH3peI9{cXNiaX6gbJVu[W5iSHXMZUBk\WyuczDifUBqdWGpaX7nJIFv[Wy7c3nz NI\MU3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC2OlA2PSd-MUiwOlYxPTV:L3G+
colon cancer M3zPeGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1PDTFczKGi{cx?= NF;tWmpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVAvOc7:TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh7NEezN{c,OTl6OUS3N|M9N2F-
CC20 MULDfZRwfG:6aXPpeJkh[XO|YYm= Ml30O|IhcHK| MkCxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2MzOCClZXzsd{Bi\nSncjC3NkBpenNiYomgSm1ESSCvZYToc4QtKEmFNUC9NE4zPM7:TR?= MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUS3N|MoRjF7OEm0O|M{RC:jPh?=
HCT116 NULkXYdLS3m2b4TvfIlkcXS7IHHzd4F6 NEnUbFA4OiCqcoO= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVAvOjgQvF2= M37FXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
HT-29 MnnaR5l1d3SxeHnjbZR6KGG|c3H5 MV[3NkBpenN? NVGyb4F4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE[PQ1GgcYV1cG:mLDDJR|UxRTFwNN88US=> M3HQZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
Hs578Bst M1zTVmN6fG:2b4jpZ4l1gSCjc4PhfS=> MX:3NkBpenN? M{iyPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh{PTd6QoP0JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTBwMEVOwG0> NFHrR5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOlE3QCd-MkKzNVYyPjh:L3G+
Hs578T MXzDfZRwfG:6aXPpeJkh[XO|YYm= NHXkS4M4OiCqcoO= NYnhfIRTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jUJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTBwMkWx{txO NVvldVNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
T47D MnfYR5l1d3SxeHnjbZR6KGG|c3H5 MUe3NkBpenN? NVn5S|ROS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0xNjZ4zszN NXrBeGx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
SK-BR-3 MXnDfZRwfG:6aXPpeJkh[XO|YYm= MXy3NkBpenN? NEjEb5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2EUj2zJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTFwMElOwG0> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
MCF7 NVHhPXNzS3m2b4TvfIlkcXS7IHHzd4F6 MWi3NkBpenN? NFTES4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwQVQvP87:TR?= NUHHUYRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
Hs578Bst NGT0RXJEgXSxdH;4bYNqfHliYYPzZZk> MXG0NEB2VQ>? Ml;ZO|IhcHK| NU\TO2xrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jCd5Qh[2WubIOgZZQhPDBidV2gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4wtKEmFNUC9OFcvP87:TR?= NV;1O493RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
CHO NHTY[o1HfW6ldHnvckBie3OjeR?= M4D5dpBKSzVyII\hcJVmeyCob4Kgd49lcXWvIH\seY9z\XOlZXnuJEgyOCC3TTmgeZB1[WunIHnuJG9CXFBzQkGteJJidnOoZXP0[YQhS0iRIHPlcIx{NCCLQ{WwQVMvOjN3OUVOwG0> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MUSxOUc,OjN3N{G0NVU9N2F-
CHO MXrGeY5kfGmxbjDhd5NigQ>? MlTBdGlEPTBidnHseYV{KG[xcjDzc4RqfW1iZnz1c5Jme2OnaX6gLFExKHWPKTD1dJRic2ViaX6gU2FVWDGEMz30doFve2[nY4Tl[EBEUE9iY3XscJMtKEmFNUC9NVMvOTh{Nt88US=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MUSxOUc,OjN3N{G0NVU9N2F-
Hs683 NHLySZdEgXSxdH;4bYNqfHliYYPzZZk> M2jaWlMh\GG7cx?= NFvk[plEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJezZ6MzDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODUQvF2= Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
A549 M3rnRmN6fG:2b4jpZ4l1gSCjc4PhfS=> M2DUWVMh\GG7cx?= NEPRTmVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPc7:TR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
PC3 NEi0eItEgXSxdH;4bYNqfHliYYPzZZk> M1fDRlMh\GG7cx?= M{jWOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFc2|ryP NYr2[mJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
U373 MX7DfZRwfG:6aXPpeJkh[XO|YYm= M2O1cFMh\GG7cx?= MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVN|c{KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOFbPxE1? NFPiO4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
SK-MEL-28 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NWHzTW5bOyCmYYnz M1\1OWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yPEBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMk[2{txO MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
MCF7 MlrvR5l1d3SxeHnjbZR6KGG|c3H5 M1fER|Mh\GG7cx?= NHv3Z3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE41OjcQvF2= Mnq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
Drosophila Schneider cells M4D0TWZ2dmO2aX;uJIF{e2G7 Mmq2RY51[WexbnnzeEBi[3Srdnn0fUBifCC2cnHud4FkfGm4YYTpc44h\G:vYXnuJI9nKFKRUnfhcY1ifCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDEdo9{d3CqaXzhJHNkcG6naXTldkBk\WyuczDjc{1mgHC{ZYPzbY5oKEejbEStSG5CKGKrbnTpcoch\G:vYXnuMEBKSzVyPUNOwG0> NFLRS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0NFQ5Pid-MkSwOFA1QDZ:L3G+
Drosophila Schneider cells NHzlUZRHfW6ldHnvckBie3OjeR?= NVPTWlVMSW62YXfvcol{fCCjY4Tpeol1gSCjdDD0doFve2GldHn2ZZRqd25iZH;tZYlvKG:oIGLPVodidW2jdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBFem:|b4DobYxiKFOlaH7lbYRmeiClZXzsd{Bkdy2neIDy[ZN{cW6pIFfhcFQuTE6DIHLpcoRqdmdiZH;tZYlvNCCLQ{WwQVLPxE1? NYT6eo15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFA1QDZpPkK0NFQxPDh4PD;hQi=>
RKO-AS45-1 NGexXnhEgXSxdH;4bYNqfHliYYPzZZk> NU\zPXJ6PDhiaILz MlHwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVmtQNUGVNEWtNUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwNENOwG0> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa MVnDfZRwfG:6aXPpeJkh[XO|YYm= MX60PEBpenN? MkLqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuNu69VQ>? M2CyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa MVvGeY5kfGmxbjDhd5NigQ>? MmP3NVUxKG6P MkfNNlQhcHK| MUjJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> MoTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa NVP4SpZRTnWwY4Tpc44h[XO|YYm= MoHqNVUxKG6P NWrwflVSOjRiaILz MnzMTY5pcWKrdHnvckBw\iCQYTirLU9MMCtrIFHUVIF{\SCrbjDoeY1idiCKZVzhJINmdGy|IHH0JFE2OCCwTTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoc> MlflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa NHnuZXJHfW6ldHnvckBie3OjeR?= MX2xOVAhdk1? M2TJcVI1KGi{cx?= NEHhUmtKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? NEjHfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa NUDQNYVJTnWwY4Tpc44h[XO|YYm= MUexOVAhdk1? M{TONVI1KGi{cx?= NULDVZBRUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NWTKdJFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa MlvwSpVv[3Srb36gZZN{[Xl? M1;mNFE2OCCwTR?= MYCyOEBpenN? NX7iNIZpUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa MornSpVv[3Srb36gZZN{[Xl? NVvCR3VROTVyIH7N Mn7QNlQhcHK| M2fN[GlvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o NXHRUlkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NHfE[2xHfW6ldHnvckBie3OjeR?= MXSxOVAhdk1? MlruNlQhcHK| NXPBU4xjUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NIXIS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa Mm\WSpVv[3Srb36gZZN{[Xl? NVTWVWliOTVyIH7N NVL5WWNtOjRiaILz NUnBd2IyUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NWjIWHhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
Kasumi-1 MlTzR5l1d3SxeHnjbZR6KGG|c3H5 NXLjOFBjPDhiaILz M{m1TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtie3WvaT2xJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NF0xNjB7M988US=> NWnqWphwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
MV4-11 NEewb5VEgXSxdH;4bYNqfHliYYPzZZk> M2\3ZlQ5KGi{cx?= Mn\BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlEyOc7:TR?= NUnVe3JsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
HT-29 NXe4dlRuS3m2b4TvfIlkcXS7IHHzd4F6 NUi1VFFjPzJiaILz MnTOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuN|jPxE1? M3XBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUizPFQzLz5{N{m4N|g1OjxxYU6=
H1299 NYfSdmN3S3m2b4TvfIlkcXS7IHHzd4F6 MkK2NlQhcHK| MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDINVI6QSClZXzsd{BqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60Ou69VQ>? NVWye5p2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
CCD-112CoN NF7re4tEgXSxdH;4bYNqfHliYYPzZZk> NVO3RldUPzJiaILz NYq1eGZNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OGLUGxNmNwViClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyxiSVO1NF0zNjUQvF2= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl6M{i0Nkc,Ojd7OEO4OFI9N2F-
DU145 MknoSpVv[3Srb36gZZN{[Xl? NHnwSVM2OCC3TR?= NUXMZmNGPSCqcoO= NFnR[VNKdmirYnn0bY9vKG:oIF7hL{9MMyCDVGDhd4UheHWvcDDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZZQhPTBidV2gcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nliRoXyZU0zN0GPIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYm= M33RflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 NXSzfpJkTnWwY4Tpc44h[XO|YYm= NVe5cHZyPTBidV2= NHLpXoU2KGi{cx?= M2DJ[WlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= NWHmXlNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
DU145 NULlNJA2TnWwY4Tpc44h[XO|YYm= NFrWTHg2OCC3TR?= Ml6xOUBpenN? NYLYS3NMUW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 NEnyUWpHfW6ldHnvckBie3OjeR?= MVS1NEB2VQ>? NUjr[ohXPSCqcoO= MoXDTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 MlvvSpVv[3Srb36gZZN{[Xl? NYTqV|Z1PTBidV2= M2jDZVUhcHK| MlvkTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 NG\BT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+
DU145 NYGwR3hGTnWwY4Tpc44h[XO|YYm= NV3DS5pZPTBidV2= NVrifZZOPSCqcoO= M4K4fGlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= NV:xZWp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
DU145 MlvHSpVv[3Srb36gZZN{[Xl? MU[1NEB2VQ>? MUm1JIhzew>? MYXJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? M4XlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 MUPGeY5kfGmxbjDhd5NigQ>? NWjjcmc6PTBidV2= MXi1JIhzew>? M2XMbWlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= M1nBSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
Assay
Methods Test Index PMID
Western blot p-Src / Src / p-EGFR / EGFR / p-STAT3 / STAT3 ; p-PI3K / PI3K / p-AKT / AKT / p-MEK / MEK / p-ERK / ERK / p-FAK / FAK / p-SAPK/JNK / p-Paxillin / Paxillin / p-p130Cas / p130Cas ; Nrf2 25955608 30735911
Growth inhibition assay Cell viability 25955608

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.

2mg/mL

Chemical Information

Molecular Weight 780.94
Formula

C41H64O14

CAS No. 20830-75-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05137626 Not yet recruiting Drug: AT-527 + digoxin Healthy Volunteers Study Atea Pharmaceuticals Inc.|Hoffmann-La Roche November 2021 Phase 1
NCT05014087 Recruiting Drug: Intravenous digoxin Acute Alcoholic Hepatitis|Chemical and Drug Induced Liver Injury|Alcohol-Induced Disorders|Steatohepatitis Caused by Ingestible Alcohol Yale University October 8 2021 Phase 2
NCT03559868 Recruiting Drug: Digoxin|Other: Placebo Inflammatory Response Yale University March 1 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Digoxin (NSC 95100) | Digoxin (NSC 95100) supplier | purchase Digoxin (NSC 95100) | Digoxin (NSC 95100) cost | Digoxin (NSC 95100) manufacturer | order Digoxin (NSC 95100) | Digoxin (NSC 95100) distributor